Effects of Plasmalogen in Patients with Mild Cognitive Impairment

J Alzheimers Dis Parkinsonism 2018;8(1).
Fujino, et al.

A total of 178 patients with mild cognitive impairment (MCI) were administered either scallop-derived plasmalogen (1 mg/day) or a placebo for 24 weeks. Changes in cognitive function were evaluated using the MMSE-J (the Japanese version of the Mini-Mental State Examination).　As a result, the plasmalogen group showed a significant increase in total MMSE-J scores after the intervention compared with baseline (*p < 0.05).　Furthermore, post-intervention comparisons revealed that the plasmalogen group demonstrated a significant improvement compared with the placebo group in “orientation to place,” one of the cognitive assessment domains (p = 0.003). Orientation to place refers to the ability to recognize one’s current location.